Susan R. Peck, PhD

While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.

Increased understanding of the molecular mechanisms underlying the pathogenesis of hematologic cancers has led to the development of several promising new classes of targeted therapies.

Results of recent trials investigating novel therapies for chronic lymphocytic leukemia were discussed at the 16th Annual International Congress on Hematologic Malignancies.

The prognosis for a significant fraction of DLBCL patients that relapse while receiving the current standard treatment of R-CHOP-21 remains poor.

Patients with hormone receptor-positive metastatic breast cancer (MBC) frequently respond to multiple lines of endocrine therapy but, unfortunately, resistance eventually develops.